Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels.
London, United Kingdom
The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. Its work is helping to understand why disease develops and to find new ways to treat, diagnose and prevent illnesses…
Sponsors of the World Neuroscience Innovation Forum comprise a select group of industry leading organizations committed to innovation and its ability to improve care. Joining the World Forum Community signals your active involvement in the premier venue for academic and corporate collaboration.
Sponsorship brings visibility and insight to strategic decision-making on the most important industry and cross-industry related issues, and high levels of brand visibility in an environment ideally suited to engaging with the most senior leaders in global health care and medical innovation.
If you wish to join us as a sponsor, please contact Anika Heavener, Senior Manager for Strategic Alliances, for further details: